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MaOBJECTIVES This study sought to determine the beneﬁts of adding oral anticoagulation therapy in patients with
anterior wall ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary inter-
vention (PCI).
BACKGROUND Guidelines suggest adding oral anticoagulation to dual-antiplatelet therapy in patients with STEMI
when left ventricular apical akinesis or dyskinesis is present to prevent thromboembolic complications. The beneﬁts
of this triple therapy remain unknown.
METHODS We identiﬁed patients with anterior STEMI referred (PCI) between July 2004 and June 2010 with apical
akinesis or dyskinesis on transthoracic echocardiography. We compared patients who were prescribed warfarin to patients
who were not. We excluded patients with left ventricular thrombus, a separate need for oral anticoagulation, and
previous intracranial bleeding. The primary outcome was a composite of net adverse clinical events (NACE) consisting
of all-cause mortality, stroke, reinfarction, and major bleeding at 180 days.
RESULTS Among 460 patients who qualiﬁed, 131 were discharged on warfarin therapy and 329 without warfarin
therapy. Dual-antiplatelet therapy was prescribed for 99.2% of the patients in the warfarin group and for 97.6% of the
patients in the no warfarin group (p ¼ 0.46). Compared with patients in the no warfarin group, patients in the warfarin
group had higher rates of NACE (14.7% vs. 4.6%, p ¼ 0.001), death (5.4% vs. 1.5%, p ¼ 0.04), stroke (3.1% vs. 0.3%,
p ¼ 0.02), and major bleeding (8.5% vs. 1.8%, p < 0.0001). By propensity score analysis, allocation to warfarin therapy
was an independent predictor of NACE (odds ratio [OR]: 4.01, 95% conﬁdence interval: 2.15 to 7.50, p < 0.0001). In a
separate multivariable analysis, the OR of NACE remained signiﬁcantly higher compared with patients who were not
prescribed warfarin (OR: 3.13, 95% conﬁdence interval: 1.34 to 7.22, p ¼ 0.007).
CONCLUSIONS Our results do not support the addition of warfarin therapy after primary PCI in patients with apical
akinesis or dyskinesis. (J Am Coll Cardiol Intv 2015;8:155–62) © 2015 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
DAPT = dual-antiplatelet
therapy
INR = international normalized
ratio
LV = left ventricular
NACE = net adverse clinical
event(s)
OR = odds ratio
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
TTE = transthoracic
echocardiography
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156and a P2Y12 inhibitor reduces stent throm-
bosis and reinfarction after coronary stenting
compared with aspirin alone or aspirin plus
warfarin (1–4).
In some patients treated with primary PCI,
there is need to add oral anticoagulants to
prevent thromboembolic events. However,
there is mounting evidence that the combi-
nation of DAPT and oral anticoagulation
(triple therapy) is associated with bleeding
(5–8). In the era of primary PCI, there are
limited data on clinical outcomes in patients
with STEMI who are prescribed triple therapy.
The 2013 American College of Cardiology/
American Heart Association STEMI guidelines
recommend oral anticoagulation therapy
with warfarin in addition to DAPT in patients
with left ventricular (LV) mural thrombus
(Class 2a recommendation) and in patientswith apical akinesis or dyskinesis (class 2b recom-
mendation) for at least 3 months (9).SEE PAGE 163The transthoracic echocardiography (TTE) is the
most widely used tool to assess for LV thrombus and
wall motion abnormalities after anterior STEMI.
Although there is consensus to add oral anticoagu-
lants when LV thrombus is identiﬁed, the role of an-
ticoagulants in patients with apical akinesis
or dyskinesis without demonstrated LV thrombus
remains controversial. Moreover, the safety of this
approach in the latter group is poorly documented
and represents a major therapeutic dilemma. As ran-
domized trials have yet to be done, we used our
database to provide insight into this important man-
agement question.
METHODS
PATIENT SELECTION. During the study period, the
University of Ottawa Heart Institute provided primary
PCI as the dominant reperfusion strategy for STEMI
patients presenting in our local health network (10).
Since the inception of our regional STEMI system, all
data pertaining to primary PCI have been entered in
the institution’s database. In this context, we identi-
ﬁed all patients referred for primary PCI between July
2004 and June 2010 presenting with anterior wall
STEMI deﬁned as the following: 1) ischemic chest
discomfort of at least 30-min duration and onset
within 12 h of presentation; and 2) at least 1 mm
(0.1 mV) ST-segment elevation in $2 contiguous
precordial leads on a standard 12-lead electrocardio-
gram. We included only patients in whom akinesis ordyskinesis was identiﬁed in at least 1 LV apical
segment on TTE performed within 7 days of hospi-
talization. Patients were then divided into 2 groups
on the basis of initiation of warfarin therapy during the
acute hospitalization. The following were criteria for
exclusion: warfarin at the time of admission; atrial
ﬁbrillation, deep vein thrombosis, pulmonary embo-
lism, mechanical prosthetic cardiac valve, or LV
thrombus; bypass surgery during the same admission;
previous intracranial bleeding; in-hospital bleeding or
stroke occurring before baseline TTE; and TTE was of
suboptimal quality, not performed, or performed >7
days after the admission. We also excluded patients
who died within 72 h of admission or in the setting of
ongoing cardiogenic shock or anoxic encephalopathy.
STANDARD THERAPY. All patients received 160 mg
chewable aspirin, 600 mg oral clopidogrel, and
60 U/kg intravenous unfractionated heparin to a
maximal dose of 4,000 U before catheterization. The
PCI procedure was performed according to the stan-
dard of practice. After the PCI, aspirin 81 mg/day was
prescribed to be continued indeﬁnitely and clopi-
dogrel 75 mg/day for up to 1 year. Patients were
monitored in the cardiac intensive care unit and,
when deemed stable, were transferred to the ward.
All patients were treated with intravenous heparin
after the PCI until TTE was performed. The decision to
add warfarin was at the discretion of the treating
cardiologist. In patients deemed not to require oral
anticoagulants, heparin was discontinued immedi-
ately after TTE; however, it was continued as bridging
therapy in patients started on warfarin. In these pa-
tients, warfarin was prescribed for 3 to 6 months and
the international normalized ratio (INR) was adjusted
between 2.0 and 3.0 as per prevailing guidelines (11,12).
Patients were followed in the clinic at the University of
Ottawa Heart Institute, and telephone follow-up was
performed when a visit was not possible.
ECHOCARDIOGRAPHY. TTE images were acquired
using the following systems: the iE33 Echocardiog-
raphy System (Philips Healthcare, Andover, Massa-
chusetts), the Sono’s 5500 (Philips Healthcare) or the
Vivid 7 (GE Healthcare, Milwaukee, Wisconsin). Re-
gional LV function was assessed using a 16-segment
model as recommended by the American Society of
Echocardiography (13). This model consists of 6
segments at the base, 6 at the midventricular level,
and 4 at the apex. Each segment was analyzed indi-
vidually and scored on the basis of its motion and
systolic thickening using the following recommended
scale: normal or hyperkinesis ¼ 1; hypokinesis ¼ 2;
akinesis ¼ 3; dyskinesis ¼ 4; and aneurysmal ¼ 5. At
least 1 of the 4 apical segments needed an individual
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157score of 3, 4, or 5 to meet study inclusion criteria. A
LV apical score was generated by summing the scores
of the 4 individual apical segments. LV ejection
fraction was calculated using Simpson’s rule.
Contrast agents were used to better visualize LV wall
segments and to detect LV thrombus according to
American Society of Echocardiography guidelines
(14). All images were interpreted by cardiologists with
level 3 certiﬁcation in echocardiography (15). The
University of Ottawa Heart Institute echocardiogra-
phy laboratory is accredited by the Intersocietal
Commission for the Accreditation of Echocardiogra-
phy Laboratories.
ENDPOINTS AND DEFINITIONS. The objective of this
study was to determine the beneﬁts of adding
warfarin therapy in patients with anterior STEMI
initially managed with primary PCI and in whom
apical akinesis or dyskinesis was demonstrated on
TTE performed within the ﬁrst week of hospitaliza-
tion. The primary outcome was a composite of net
adverse clinical events (NACE) consisting of all-cause
mortality, stroke, reinfarction, and major bleedingFIGURE 1 Flow of Patients in the Study
Between July 2004 and June 2010, a total of 838 consecutive patients
ﬁgure, 460 patients qualiﬁed for the study: 131 were discharged on war
PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevatiwithin 180 days of the index TTE. A stroke was
deﬁned as a new neurological deﬁcit of >24-h dura-
tion and was classiﬁed as hemorrhagic or non-
hemorrhagic on the basis of computed tomography or
magnetic resonance imaging of the head. Reinfarction
was deﬁned as recurrent chest pain associated with
re-elevation of the ST segments in association with
re-elevation of cardiac enzymes (twice the upper limit
of the normal range) or angiographic documentation
of reocclusion of the infarct-related artery. Major
bleeding was deﬁned as the need for at least 1 blood
transfusion or intracranial bleeding conﬁrmed by
imaging. In patients prescribed warfarin, bleeding
was not included as an event if the event occurred
more than 7 days after stopping this therapy. A com-
posite of major adverse cardiovascular events con-
sisting of death, myocardial infarction, and stroke
was a secondary endpoint. We also evaluated for def-
inite or probable stent thrombosis as deﬁned by the
Academic Research Consortium criteria (16). The
study was approved by the institutional review board
of the University of Ottawa Heart Institute.presenting with anterior STEMI were screened. As shown in the
farin therapy and 329 were discharged without warfarin therapy.
on myocardial infarction.
TABLE 1 Baseline Ch
Characte
Age, yrs
Male
Hypertension
Diabetes mellitus
Current smoker
History of hyperlipidem
Previous myocardial in
Previous stroke
Previous angioplasty
Previous bypass surger
Heart rate, beats/min
Systolic blood pressure
Diastolic blood pressur
Killip class
I
II
III
IV
Body mass index, kg/m
Creatinine clearance, m
Baseline hemoglobin, g
Time to TTE, days
Left ventricular ejectio
Left ventricular apical
Discharge medications
Aspirin
Clopidogrel
Dual-antiplatelet the
Angiotensin-converti
Angiotensin receptor
Beta-blocker
Statin
Values are mean  SD, n (
TTE ¼ transthoracic ech
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158STATISTICAL ANALYSIS. Categorical variables are
presented as frequencies (percentages) and were
compared by the Fisher exact test or the chi-square
test, as appropriate. Normally distributed continuous
variables are shown as mean  SD and were compared
with the Student t test. Nonnormally distributed vari-
ables are shown as median (interquartile range) and
were analyzed with the Mann-Whitney U test. The LV
ejection fraction and the apical score were compared
between baseline and follow-up TTE studies using a
paired t test. A propensity score was generated using
the baseline variables, and the impact of warfarin
therapy on NACE at 180 days was assessed on the basis
of a propensity score analysis using inverse probability
weighting in a logistic regression model. In addition, a
multivariable analysis using a logistic regression
model was performed to determine the independent
effect of adding warfarin therapy on NACE, controllingaracteristics of Patients
ristic
Warfarin
(n ¼ 131)
No Warfarin
(n ¼ 329) p Value
61.5  14.1 60.6  14.2 0.53
96 (73.3) 248 (75.4) 0.64
54 (42.5) 129 (40.1) 0.67
22 (17.0) 43 (13.2) 0.30
51 (39.2) 137 (42.3) 0.60
ia 43 (34.4) 120 (37.7) 0.58
farction 10 (7.8) 32 (9.9) 0.59
8 (6.2) 13 (4.0) 0.33
11 (8.5) 20 (6.2) 0.41
y 2 (1.5) 1 (0.3) 0.20
83.9  18.7 81.3  18.8 0.13
, mm Hg 136.2  27.7 138.4  28.4 0.46
e, mm Hg 84.2  16.6 83.1  17.7 0.63
0.56
104 (79.4) 279 (84.8)
19 (14.5) 38 (11.6)
3 (2.3) 5 (1.5)
5 (3.8) 7 (2.1)
2 27.9  5.7 27.4  5.0 0.35
l/min 84.2  35.8 89.7  37.7 0.14
/l 147.4  17.1 144.0  17.5 0.06
2 (1–2) 2 (1–3) 0.006
n fraction, % 39.0  8.5 44.7  8.2 <0.0001
score 12.9  2.2 11.1  1.9 <0.0001
131 (100) 325 (98.8) 0.58
130 (99.2) 325 (98.9) 1.00
rapy 130 (99.2) 320 (97.6) 0.46
ng enzyme inhibitor 118 (90.1) 283 (86.0) 0.28
blocker 4 (3.1) 15 (4.6) 0.61
104 (93.7) 295 (96.1) 0.30
126 (96.2) 323 (98.2) 0.31
%), or median (interquartile range).
ocardiography.for differences in baseline variables with p < 0.10 by
univariable analysis. A 2-sided p value #0.05 was
considered statistically signiﬁcant. Analyses were
conducted using SAS version 9.13 (SAS Institute, Cary,
North Carolina).
RESULTS
PATIENTS. We screened 838 consecutive patients
presenting with anterior STEMI between July 2004
and June 2010. TTE was performed in 751 of
these patients, and LV thrombus was reported in
22 patients (2.9%). As shown in Figure 1, of 460 pa-
tients who qualiﬁed for the study, 131 patients were
discharged on warfarin therapy and 329 were dis-
charged without warfarin therapy. Baseline charac-
teristics of the patients are shown in Table 1. The 2
groups were relatively well matched except for the
following: in patients treated with warfarin therapy,
hemoglobin was higher (147.4  17.1 g/l vs. 144.0 
17.5 g/l); the LV apical score was higher (12.9  2.2 vs.
11.1  1.9, p < 0.0001); and the LV ejection fraction
was lower (39.0  8.5 vs. 44.7  8.2, p < 0.0001). At
discharge, DAPT was prescribed for 99.2% of the
patients in the warfarin group (i.e., triple therapy)
and for 97.6% of the patients in the no warfarin group
(p ¼ 0.46). The distribution of patient’s apical scores
in the 2 groups is depicted in Figure 2.
PROCEDURE RESULTS. All patients underwent
cardiac catheterization. As shown in Table 2, more
patients in the warfarin group underwent primary PCI
(100% vs. 95.4%, p ¼ 0.01), and bivalirudin was
used less frequently in this group (22.9% vs. 34.3%, p¼
0.02). Compared with patients not prescribed warfarin
therapy, the proportion of patients with Thrombolysis
In Myocardial Infarction (TIMI) ﬂow grade 3 at base-
line in the warfarin group was lower (22.6% vs. 13.0%,
p ¼ 0.02); however, there was no difference in the
proportion of patients with TIMI ﬂow grade 3 after
the procedure (92.3% vs. 88.6%, p ¼ 0.20).
FOLLOW-UP ECHOCARDIOGRAPHY. During the follow-
up period, TTE was repeated in 190 patients: 71 pa-
tients in the warfarin group and 119 in the no warfarin
group. LV thrombus was not observed in any
patient. In the warfarin group, the LV ejection frac-
tion increased from 38.3  8.1 at baseline to 42.0 
11.4 at follow-up (p ¼ 0.004), and the apical score
decreased from 12.6  2.0 to 11.3  4.2 (p ¼ 0.02).
Similarly, in the no warfarin group, the LV ejec-
tion fraction increased from 43.6  8.5 to 47.8  11.0
(p < 0.0001), and the apical score decreased from
11.3  1.8 to 9.1  3.9 (p < 0.0001). Apical akinesis or
dyskinesis was no longer present in 21% of patients
FIGURE 2 Distribution of LV Apical Scores in the 2 Groups
An apical score was generated by summing the scores of the 4 individual apical segments
reported on the transthoracic echocardiography: the range for an apical score was 6 to 20.
The ﬁgure highlights the extent of overlap between the 2 groups. LV ¼ left ventricular.
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159in the warfarin group and in 41% of patients in the
no warfarin group.
CLINICAL RESULTS. Clinical events are shown in
Table 3. Complete follow-up was available in 99.0% of
the patients. Compared with patients who were not
prescribed warfarin, patients who were prescribed
warfarin had a higher rate of NACE at 180 days
(14.7% vs. 4.6%, p ¼ 0.001). The rate of death was
higher in patients prescribed warfarin (5.4% vs. 1.5%,
p ¼ 0.04, and the rate of stroke was also higher
(3.1% vs. 0.3%, p ¼ 0.02). Two patients in the warfarin
group (1.5%) versus none in the no warfarin group
experienced a hemorrhagic stroke (p ¼ 0.08). There
was no difference in the rates of reinfarction between
the 2 groups. The need for blood transfusion was
higher in the warfarin group (7.8% vs. 1.8%,
p ¼ 0.004), as was major bleeding (blood transfusion
or hemorrhagic stroke) (8.5% vs. 1.8%, p < 0.0001).
Bleeding at the access site used for cardiac catheter-
ization occurred in 4 patients (3.1%) in the warfarin
group and in none of the patients in the no warfarin
group (p ¼ 0.006). One patient in the warfarin group
received a blood transfusion more than 1 week after
stopping warfarin; however, by protocol, this was not
included in the analysis as a bleeding event. The
median length of stay during the initial hospitaliza-
tion was longer in the warfarin group (8 days vs.
5 days, p < 0.0001). The number of readmissions was
also higher (19.4% vs. 9.2%, p ¼ 0.004).
The impact of warfarin therapy on NACE was
assessed by propensity score analysis. The odds ratio
(OR) of NACE was noted to be higher in the group of
patients treated with warfarin (OR: 4.01, 95% conﬁ-
dence interval [CI]: 2.15 to 7.50, p < 0.0001). The
C-statistic was 0.67. The impact of warfarin therapy
was also assessed in a multivariable logistic regres-
sion analysis. The following variables with p < 0.10
were entered in the model: patient group (warfarin
vs. no warfarin), admission hemoglobin level, femoral
access, PCI done at initial angiography, bivalirudin
used during the PCI, initial TIMI ﬂow grade 3, time
from admission to TTE, baseline LV apical score,
baseline LV ejection fraction, and shock during
the initial hospitalization. In patients prescribed
warfarin, the OR of NACE remained signiﬁcantly
higher compared with patients who were not pre-
scribed warfarin (OR: 3.13, 95% CI: 1.34 to 7.22,
p ¼ 0.007). The C-statistic was 0.72.
DISCUSSION
In this study, the addition of warfarin to prevent
thromboembolic complications in patients presentingwith anterior STEMI treated with primary PCI was
associated with more adverse clinical events com-
pared with patients who were managed without
warfarin therapy. Our results suggest that in the
absence of LV thrombus, the addition of warfarin is
not indicated for the management of patients with
apical akinesis or dyskinesis on TTE.
Compared with aspirin alone, clopidogrel added to
aspirin reduces cardiovascular events in patients with
acute coronary syndrome (17). Likewise, DAPT con-
sisting of aspirin and a thienopyridine reduces car-
diac events after coronary stent placement compared
with aspirin alone or aspirin with oral anticoagulants
(1–4). Hence, DAPT has become the standard of care in
patients presenting with an acute coronary syndrome
and in patients treated with coronary stenting.
Triple therapy consists of oral anticoagulant ther-
apy plus DAPT (9). In some patients with acute cor-
onary syndrome, warfarin therapy is also needed for
protection against thromboembolic disease because
of other coexisting medical conditions such as atrial
ﬁbrillation, prosthetic mechanical valves, venous
thromboembolic disease, and hypercoagulable disor-
ders. The current American College of Cardiology/
American Heart Association STEMI guidelines
indicate that anticoagulant therapy with a vitamin K
antagonist is reasonable for patients with STEMI and
asymptomatic LV mural thrombi and may be consid-
ered for patients with anterior apical akinesis or
TABLE 2 Procedural Results
Variable
Warfarin
(n ¼ 131)
No Warfarin
(n ¼ 329)
p
Value
Catheterization performed 131 (100.0) 329 (100.0)
Femoral access 111 (84.7) 299 (90.9) 0.07
PCI performed 131 (100.0) 314 (95.4) 0.01
Stenting performed 127 (96.9) 310 (94.2) 0.34
Stents per patient 1.5  0.8 1.4  0.8 0.21
Drug-eluting stent implanted 39 (30.7) 107 (34.5) 0.50
Glycoprotein IIb/IIIa inhibitor use 56 (41.8) 121 (36.8) 0.24
Bivalirudin use 30 (22.9) 113 (34.3) 0.02
Aspiration catheter use 42 (34.1) 97 (32.1) 0.73
Multivessel disease 52 (39.7) 141 (42.9) 0.60
Coronary ﬂow at baseline 0.03
TIMI grade
0 90 (68.7) 176 (53.8)
1 11 (8.4) 31 (9.5)
2 13 (9.9) 46 (14.1)
3 17 (13.0) 74 (22.6)
Coronary ﬂow after procedure 0.07
TIMI grade
0 0 (0.0) 4 (1.2)
1 1 (0.8) 5 (1.5)
2 14 (10.7) 16 (4.9)
3 116 (88.6) 301 (92.3)
Stenosis, % of luminal diameter
Before procedure 97.8  8.6 97.2  7.1 0.46
After procedure 2.0  11.0 0.7  6.4 0.19
Door-to-balloon time, min 98 (72-130) 96 (70-134) 0.48
Onset-to-balloon time, min 211 (158-360) 205 (143-347) 0.32
Therapeutic hypothermia use 2 (1.5) 4 (1.2) 1.00
Intra-aortic balloon counter
pulsation use
5 (3.8) 7 (2.1) 0.33
Values are n (%), mean  SD, or median (interquartile range).
PCI ¼ percutaneous coronary intervention.
TABLE 3 Clinical Outcomes
Outcomes
Warfarin
(n ¼ 131)
No Warfarin
(n ¼ 329) p Value
In-hospital
Death 0 (0.0) 0 (0.0) —
Reinfarction 1 (0.8) 0 (0.0) 0.29
Stroke 1 (0.8) 1 (0.3) 0.49
Hemorrhagic 0 (0) 0 (0)
Blood transfusion 4 (3.1) 0 (0.0) 0.006
Major bleeding 4 (3.1) 0 (0.0) 0.006
Death, reinfarction or stroke 2 (1.5) 1 (0.3) 0.20
Death, reinfarction, stroke or
major bleeding
6 (4.6) 1 (0.3) 0.003
Stent thrombosis 1 (0.8) 0 (0.0) 0.29
Cardiogenic shock 14 (10.7) 10 (3.0) 0.002
Length of stay, days 8 (7–11) 5 (4–7) <0.001
Cumulative events at 180 days
Death 7 (5.4) 5 (1.5) 0.04
Reinfarction 2 (1.6) 5 (1.5) 1.00
Stroke 4 (3.1) 1 (0.3) 0.02
Hemorrhagic 2 (1.5) 0 (0) 0.08
Blood transfusion 10 (7.8) 6 (1.8) 0.004
Major bleeding 11 (8.5) 6 (1.8) <0.0001
Death, reinfarction
or stroke
12 (9.3) 9 (2.8) 0.005
Primary outcome: death,
reinfarction, stroke,
or major bleeding
19/129 (14.7) 15/327 (4.6) 0.001
Stent thrombosis 1/129 (0.8) 3/327 (0.9) 1.000
Hospital readmission 25 (19.4) 30 (9.2) 0.004
Values are n (%), median (interquartile range), or n/N (%).
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160dyskinesis (9). To assess the beneﬁts associated with
the latter indication, we excluded patients with LV
thrombus as well as patients with a coexisting con-
dition needing warfarin therapy.
The risk of major bleeding with triple therapy has
been reported to be 2 to 5 times higher compared with
DAPT alone in patients treated with coronary stenting
(5–8). However, outcome data on the use of triple
therapy in patients treated with primary PCI remain
limited. In our study, 99.2% of the patients in the
warfarin group were discharged on DAPT (i.e.,
received triple therapy), whereas 97.6% of the
patients in the no warfarin group were discharged on
DAPT. In a recent analysis from the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial, patients
with STEMI treated with triple therapy versus DAPT
had comparable ischemic outcomes but signiﬁcantly
increased rates of major bleeding at both early andlong-term follow-up (18). Our study differs in that we
included only patients with apical akinesis or dyski-
nesis documented by TTE, and we excluded patients
with LV thrombus and patients with other indications
for oral anticoagulation. That said, major bleeding
was also higher in patients managed with warfarin
therapy in our study. Perhaps more concerning, major
adverse cardiovascular events (i.e., death, reinfarc-
tion, stroke), were more frequent in the warfarin
group, including a higher rate of strokes with a trend
toward more hemorrhagic strokes in this group.
Most studies comparing outcomes between triple
therapy and DAPT typically included patients with
different indications for warfarin therapy, the most
frequent being atrial ﬁbrillation. In 1 retrospective
study involving 426 patients with atrial ﬁbrilla-
tion undergoing coronary stenting, nonanticoagula-
tion with warfarin was an independent predictor of
increased mortality (19). A recent meta-analysis of
nonrandomized studies suggested that triple therapy
is more efﬁcacious than DAPT in the prevention of
major adverse cardiovascular events including all-
cause mortality (20). However, in this meta-analysis,
warfarin therapy was prescribed mostly for atrial
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161ﬁbrillation. Therefore, these results were not com-
pletely unexpected given that a large randomized
trial previously demonstrated the superior beneﬁts of
warfarin therapy for the prevention of vascular
events compared with aspirin plus clopidogrel in
patients with atrial ﬁbrillation (21). Because we
excluded patients with atrial ﬁbrillation and other
medical conditions necessitating oral anticoagulant
therapy, patient selection may explain why warfarin
therapy was not beneﬁcial in our STEMI patients.
Of note, we excluded 22 patients with LV thrombus
(2.9%) from this study because most physicians
would have been compelled to use anticoagulants in
these patients. This incidence is lower than the 6.2%
to 23.5% reported in previous studies on patients with
anterior STEMI managed with different reperfusion
strategies (22,23) and may be related to the extent of
rapid, complete, and sustained reperfusion associ-
ated with primary PCI in our citywide program (10).
STUDY LIMITATIONS. First, because it was not a
randomized trial, it is possible that unappreciated or
immeasurable confounding variables could have
altered the results. Our study was conducted with
data from real-world patients. For this reason, we
attempted to correct imbalances between groups by
multivariable and propensity score analysis. Because
the rate of stroke in our patients managed without
warfarin was extremely low, a randomized trial
would require a very large sample size to show the
beneﬁt of reducing the rate of this complication bythe addition of warfarin therapy. As such, our results
may be the most deﬁnitive evidence to guide clini-
cians. Furthermore, bleeding events in our patients
treated with warfarin are in keeping with other re-
ports on triple therapy. There is mounting evidence
that bleeding complications after PCI are associated
with mortality (24), and several studies found a link
between blood transfusion and excess mortality
(24–27). Second, we did not report the INR measure-
ments at the time of the events. Current guidelines
recommend that the INR be tightly controlled when
warfarin therapy is added to DAPT (9). One study
found that INR values were higher in patients on tri-
ple therapy who experienced a bleeding complication
(8). However, a recent study concluded that triple
therapy compared with DAPT predisposes patients to
an increased risk of major bleeding complications
regardless of the time spent in the therapeutic anti-
coagulation range (28).
CONCLUSIONS
Our results do not support the addition of warfarin
therapy after primary PCI in patients with apical
akinesis or dyskinesis. Review of the current guide-
lines may be warranted.
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